RSA refund should be differentiated by income

Professor Ahn Jung-hoon suggested during a parliamentary debate

There is a need to reduce the refund of high-income people and benefit from the pre-deduction system for low-income people

Currently, it has been suggested that Korea should apply RSA's refund flexibly by differentiating it according to income.

 

It is suggested that the government should reduce the refund of high-income earners according to the income distribution and strengthen the guarantee of high-weakness by operating the refund of low-income earners in the form of a pre-deductible system.

 

Ahn Jung-hoon, a professor of health convergence at Ewha Womans University, made the announcement at a policy forum hosted by Kang Sun-woo today (the 25th) under the theme of "the performance of strengthening health insurance policies and task-improving drug guarantees for seriously ill patients." In Korea, 20 to 30 anticancer drugs and rare diseases are listed on the list of drug benefits every year.

 

Anti-cancer drugs are also expanding their benefit standards for around 20 drugs each year.

 

Claims for serious diseases in 2019 amounted to ₩2.2 trillion, accounting for 11.7% of total drug costs.

 

It has been increasing by 18.5% annually since 2015.

 

Among them, anti-cancer drugs increased by 16% and drugs for rare diseases increased by 28.1%.

 

Professor Ahn said that in order to develop a policy to strengthen guarantee, an evaluation based on the basis of medical non-reimbursement is necessary.

 

It is also necessary to induce reasonable medical use by strengthening the role of medical staff and giving incentives, not by the current HIRA's billing reduction system.

 

Professor Ahn suggests that expanding RSA is the right way to strengthen the guarantee of high-priced drugs.

 

He said, "Unlike other countries, the NHIS receives the drug refund amount under RSA and refunds the patient's compensation as a refund rate, but the upper limit of the health insurance premium is applied." The upper limit is applied differently depending on the income quintile, but it is also worth considering reducing the burden of low-income people and reducing the RSA refund for high-income people, Ahn suggested.

 

He said, "To reduce the burden of high-priced drugs on low-income patients, the drug that has become an RSA on the total amount should also be considered by the NHIS to prepay a certain percentage of drug claims by low-income people as collateral."